Checkpoint Therapeutics, Inc.
CKPT
$4.04
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 41.00K | 47.00K | 78.00K | 68.00K | 103.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.00K | 47.00K | 78.00K | 68.00K | 103.00K |
| Cost of Revenue | 36.15M | 27.64M | 26.77M | 36.24M | 43.57M |
| Gross Profit | -36.11M | -27.60M | -26.69M | -36.17M | -43.46M |
| SG&A Expenses | 20.06M | 9.92M | 8.80M | 8.84M | 8.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.22M | 37.56M | 35.57M | 45.08M | 52.25M |
| Operating Income | -56.17M | -37.51M | -35.49M | -45.01M | -52.15M |
| Income Before Tax | -56.24M | -46.47M | -42.47M | -52.32M | -51.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.24 | -46.47 | -42.47 | -52.32 | -51.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.24M | -46.47M | -42.47M | -52.32M | -51.85M |
| EBIT | -56.17M | -37.51M | -35.49M | -45.01M | -52.15M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.37 | -1.43 | -1.49 | -2.36 | -2.92 |
| Normalized Basic EPS | -0.86 | -0.89 | -0.93 | -1.48 | -1.82 |
| EPS Diluted | -1.37 | -1.43 | -1.49 | -2.36 | -2.92 |
| Normalized Diluted EPS | -0.86 | -0.89 | -0.93 | -1.48 | -1.82 |
| Average Basic Shares Outstanding | 158.64M | 140.35M | 117.19M | 96.36M | 75.18M |
| Average Diluted Shares Outstanding | 158.64M | 140.35M | 117.19M | 96.36M | 75.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |